Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Foote, R. L., Gilbert, J., Gillison, M. L., Haddad, R. I., Haughey, B. H., Hicks, W. L., Hitchcock, Y. J., Jimeno, A., Kies, M. S., Lydiatt, W. M., Maghami, E., McCaffrey, T., Mell, L. K., Mittal, B. B., Pinto, H. A., Ridge, J. A., Rodriguez, C. R., Samant, S., Shah, J. R., Weber, R. S., Wolf, G. T., Worden, F., Yom, S. S., McMillian, N., Hughes, M. 2015; 13 (7): 847-856

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

View details for Web of Science ID 000357901600005